Abeona Therapeutics Inc vs Bilibili Inc — how do they compare? Abeona Therapeutics Inc trades at $7.48 (market cap $421.19M), while Bilibili Inc trades at $17.57 (market cap $7.65B). The key difference: Bilibili Inc is far larger — about 18.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BILI | |
|---|---|---|
Market Cap | $421.19M | $7.65B |
Sector | Health | Media |
52-Week High | $7.45 | $35.92 |
52-Week Low | $4.17 | $15.96 |
Enterprise Value | $276.10M | $5.49B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Bilibili (BILI) trades at $17.46, down 8.06% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q1 2026 EPS of $0.19 exceeding expectations. Revenue growth remains steady at 7% year-over-year, with improving margins and a $300 million share repurchase program supporting shareholder value. Analyst sentiment remains overwhelmingly positive with 83% buy ratings.
The investment case balances strong fundamentals against technical weakness. Upside drivers include advertising growth, AI integration, and margin expansion, while risks involve competitive pressures and China's economic environment. With attractive valuation metrics and institutional support, BILI presents a compelling opportunity for patient investors despite near-term volatility.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →